Kyeong Joo Jung
Postdoctoral Scholar, Anesthesiology, Perioperative and Pain Medicine
Bio
I am a postdoctoral scholar at Stanford University, working with Dr. Nima Aghaeepour and Dr. Rebecca Rojansky. My research focuses on developing multimodal AI approaches that integrate clinical, imaging, and genomic data to advance precision medicine.
I received my PhD in Computer Science and Engineering from The Ohio State University, where my research focused on computational pathology and spatial proteomics for cancer prognosis. My current work explores the integration of longitudinal electronic health records and genomic data to improve the prediction and interpretation of genomic alterations.
All Publications
-
Deep-IMMA: an Interpretable Immune-Aware Multimodal Deep Representation Learning for Cancer Prognosis and Recurrence Prediction
edited by Yang, G., Adeli, E., DeBruijne, M., Papiez, B. W., Speidel, S., Tiwari, P., Zheng, G., Yaqub, M., Dou, Q., Rekik
SPRINGER INTERNATIONAL PUBLISHING AG. 2027: 183-193
View details for DOI 10.1007/978-3-032-38172-9_18
View details for Web of Science ID 001895661100018
-
Multi-Scale Tri-Modal Histology Dataset Integrating Tumor Morphology, Immune Patterns, and Clinical Outcomes.
bioRxiv : the preprint server for biology
2026
Abstract
Accurate prognostic assessment of prostate cancer (PCa) requires an integrated understanding of tissue morphology-encompassing cell structure, glandular architecture, and tissue organization-and the immune environment. We present Prostate-TriMod, a novel tri-modal histology dataset designed to integrate high-resolution visual morphology with spatial tissue maps, immune infiltration patterns, and clinical outcomes. This dataset, generated from the Cell DIVE™ multiplexed imaging platform, consists of three synchronized modalities: (1) multiscale virtual H&E tiles (224px, 256px, 512px, and 2040px) providing visual morphological context, (2) spatial tissue maps identifying cancerous/non-cancerous epithelial cells, stroma and immune cell populations (via TOPAZ and CAT models), and (3) text captions generated from single-cell data and patterns. The dataset includes comprehensive clinical annotations, including Grade Groups and biochemical recurrence (BCR) status. By providing high-fidelity alignment between visual features, spatial tissue maps, and textual descriptions, Prostate-TriMod empowers the development of advanced multimodal AI frameworks. We expect this resource to support reuse in multimodal representation learning, spatial analysis, and benchmarking studies that link histology morphology and immune context to clinical outcomes in prostate cancer.
View details for DOI 10.64898/2026.05.15.725535
View details for PubMedID 42239297
View details for PubMedCentralID PMC13228510
-
Annotation-Free Prediction of Cancer Cells and Glands and Spatial Analysis of Immune Cells.
bioRxiv : the preprint server for biology
2025
Abstract
Prostate cancer is classified as "immune-cold" due to limited infiltration of immune cells and no clear correlation between immune cells and clinical outcomes. However, immune cells are found in prostate cancers and the spatial relationships between these immune cells and cancer cells/glands have not been investigated, partly due to a lack of automated tools that classify both cancerous cells/glands. In this paper, we have developed an end-to-end tool (TOPAZ: Tissue Organization identification using sPAtial proteomics) that combines multiplexed single-cell protein data with histology images to: 1) predict cancerous versus non-cancerous epithelial cells using a Gaussian-mixture model; 2) predict cancerous/non-cancerous gland type using a principal curve estimation. Using TOPAZ to assign cancer and non-cancerous labels to cells and glands, we extracted multiscale spatial features from the classification results-including immune dense-region geometrical features and cell-to-gland distances-and correlated the features with risk of biochemical recurrence and cancer grade. Tissue-microarrays containing 753 cores from 217 prostate cancer patients underwent multiplexed immunofluorescent imaging (Cell DIVE, Leica) for epithelial cell markers (panCK26, S6, NaKATPase), basal cell markers (p63, CK5), a cancer cell marker (AMACR), and T cell markers (CD3, CD4, CD8, FOXP3, CD68). Cancerous/non-cancerous cell classification from TOPAZ achieved 82% sensitivity and 99% specificity against expert annotation, and the pipeline further predicted cancerous/non-cancerous glands without manual threshold tuning. Regulatory-T-cell and helper-T-cell percentages decreased, and macrophage percentage increased with grade increase (P < 0.05). When the median distance from cancerous gland centroids to the nearest regulatory or helper T-cell exceeded approximately 50 μm, the hazard of biochemical recurrence doubled (log-rank P < 0.01). The open-source Shiny app TOPAZ (https://chunglab.bmi.osumc.edu/TOPAZ) packages the workflow, predicting individual cell types and gland shapes. By combining probabilistic cell typing with gland-shape modeling, TOPAZ yields interpretable multiscale spatial features linked to prognosis and is released as an open web app for unrestricted use.
View details for DOI 10.1101/2025.11.09.687528
View details for PubMedID 41292954
View details for PubMedCentralID PMC12642328
-
AZGP1 deficiency promotes angiogenesis in prostate cancer.
Journal of translational medicine
2024; 22 (1): 383
Abstract
Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells in prostate cancer has been reported to increase proliferation and invasion. The exact role of AZGP1 in prostate cancer progression remains elusive.AZGP1 knockout and overexpressing prostate cancer cells were generated using a lentiviral system. The effects of AZGP1 under- or over-expression in prostate cancer cells were evaluated by in vitro cell proliferation, migration, and invasion assays. Heterozygous AZGP1± mice were obtained from European Mouse Mutant Archive (EMMA), and prostate tissues from homozygous knockout male mice were collected at 2, 6 and 10 months for histological analysis. In vivo xenografts generated from AZGP1 under- or over-expressing prostate cancer cells were used to determine the role of AZGP1 in prostate cancer tumor growth, and subsequent proteomics analysis was conducted to elucidate the mechanisms of AZGP1 action in prostate cancer progression. AZGP1 expression and microvessel density were measured in human prostate cancer samples on a tissue microarray of 215 independent patient samples.Neither the knockout nor overexpression of AZGP1 exhibited significant effects on prostate cancer cell proliferation, clonal growth, migration, or invasion in vitro. The prostates of AZGP1-/- mice initially appeared to have grossly normal morphology; however, we observed fibrosis in the periglandular stroma and higher blood vessel density in the mouse prostate by 6 months. In PC3 and DU145 mouse xenografts, over-expression of AZGP1 did not affect tumor growth. Instead, these tumors displayed decreased microvessel density compared to xenografts derived from PC3 and DU145 control cells, suggesting that AZGP1 functions to inhibit angiogenesis in prostate cancer. Proteomics profiling further indicated that, compared to control xenografts, AZGP1 overexpressing PC3 xenografts are enriched with angiogenesis pathway proteins, including YWHAZ, EPHA2, SERPINE1, and PDCD6, MMP9, GPX1, HSPB1, COL18A1, RNH1, and ANXA1. In vitro functional studies show that AZGP1 inhibits human umbilical vein endothelial cell proliferation, migration, tubular formation and branching. Additionally, tumor microarray analysis shows that AZGP1 expression is negatively correlated with blood vessel density in human prostate cancer tissues.AZGP1 is a negative regulator of angiogenesis, such that loss of AZGP1 promotes angiogenesis in prostate cancer. AZGP1 likely exerts heterotypical effects on cells in the tumor microenvironment, such as stromal and endothelial cells. This study sheds light on the anti-angiogenic characteristics of AZGP1 in the prostate and provides a rationale to target AZGP1 to inhibit prostate cancer progression.
View details for DOI 10.1186/s12967-024-05183-x
View details for PubMedID 38659028
View details for PubMedCentralID 321763
-
Deep learning-based automated pipeline for blood vessel detection and distribution analysis in multiplexed prostate cancer images.
Frontiers in bioinformatics
2023; 3: 1296667
Abstract
Introduction: Prostate cancer is a highly heterogeneous disease, presenting varying levels of aggressiveness and response to treatment. Angiogenesis is one of the hallmarks of cancer, providing oxygen and nutrient supply to tumors. Micro vessel density has previously been correlated with higher Gleason score and poor prognosis. Manual segmentation of blood vessels (BVs) In microscopy images is challenging, time consuming and may be prone to inter-rater variabilities. In this study, an automated pipeline is presented for BV detection and distribution analysis in multiplexed prostate cancer images. Methods: A deep learning model was trained to segment BVs by combining CD31, CD34 and collagen IV images. In addition, the trained model was used to analyze the size and distribution patterns of BVs in relation to disease progression in a cohort of prostate cancer patients (N = 215). Results: The model was capable of accurately detecting and segmenting BVs, as compared to ground truth annotations provided by two reviewers. The precision (P), recall (R) and dice similarity coefficient (DSC) were equal to 0.93 (SD 0.04), 0.97 (SD 0.02) and 0.71 (SD 0.07) with respect to reviewer 1, and 0.95 (SD 0.05), 0.94 (SD 0.07) and 0.70 (SD 0.08) with respect to reviewer 2, respectively. BV count was significantly associated with 5-year recurrence (adjusted p = 0.0042), while both count and area of blood vessel were significantly associated with Gleason grade (adjusted p = 0.032 and 0.003 respectively). Discussion: The proposed methodology is anticipated to streamline and standardize BV analysis, offering additional insights into the biology of prostate cancer, with broad applicability to other cancers.
View details for DOI 10.3389/fbinf.2023.1296667
View details for PubMedID 38323039
https://orcid.org/0000-0002-0582-1583